OBJECTIVE: The purpose of this study was to determine the clinical benefits of intense-pulsed-light therapy for the treatment of dry-eye disease caused by meibomian gland dysfunction (MGD). BACKGROUND DATA: MGD is the leading cause of evaporative dry eye disease. It is currently treated with a range of methods that have been shown to be only somewhat effective, leading to the need for advanced treatment options. METHODS: A retrospective noncomparative interventional case series was conducted with 91 patients presenting with severe dry eye syndrome. Treatment included intense-pulsed-light therapy and gland expression at a single outpatient clinic over a 30-month study. Pre/post tear breakup time data were available for a subset of 78 patients. For all patients, a specially developed technique for the treatment of dry eye syndrome was applied as a series of monthly treatments until there was adequate improvement in dry eye syndrome symptoms by physician judgment, or until patient discontinuation. RESULTS: Primary outcomes included change in tear breakup time, self-reported patient satisfaction, and adverse events. Physician-judged improvement in dry eye tear breakup time was found for 68 of 78 patients (87%) with seven treatment visits and four maintenance visits on average (medians), and 93% of patients reported post-treatment satisfaction with degree of dry eye syndrome symptoms. Adverse events, most typically redness or swelling, were found for 13% of patients. No serious adverse events were found. CONCLUSIONS: Although preliminary, study results of intense-pulsed-light therapy treatment for dry eye syndrome caused by meibomian gland dysfunction are promising. A multisite clinical trial with a larger sample, treatment comparison groups, and randomized controlled trials is currently underway.
OBJECTIVE: The purpose of this study was to determine the clinical benefits of intense-pulsed-light therapy for the treatment of dry-eye disease caused by meibomian gland dysfunction (MGD). BACKGROUND DATA: MGD is the leading cause of evaporative dry eye disease. It is currently treated with a range of methods that have been shown to be only somewhat effective, leading to the need for advanced treatment options. METHODS: A retrospective noncomparative interventional case series was conducted with 91 patients presenting with severe dry eye syndrome. Treatment included intense-pulsed-light therapy and gland expression at a single outpatient clinic over a 30-month study. Pre/post tear breakup time data were available for a subset of 78 patients. For all patients, a specially developed technique for the treatment of dry eye syndrome was applied as a series of monthly treatments until there was adequate improvement in dry eye syndrome symptoms by physician judgment, or until patient discontinuation. RESULTS: Primary outcomes included change in tear breakup time, self-reported patient satisfaction, and adverse events. Physician-judged improvement in dry eye tear breakup time was found for 68 of 78 patients (87%) with seven treatment visits and four maintenance visits on average (medians), and 93% of patients reported post-treatment satisfaction with degree of dry eye syndrome symptoms. Adverse events, most typically redness or swelling, were found for 13% of patients. No serious adverse events were found. CONCLUSIONS: Although preliminary, study results of intense-pulsed-light therapy treatment for dry eye syndrome caused by meibomian gland dysfunction are promising. A multisite clinical trial with a larger sample, treatment comparison groups, and randomized controlled trials is currently underway.
Authors: Kelly K Nichols; Gary N Foulks; Anthony J Bron; Ben J Glasgow; Murat Dogru; Kazuo Tsubota; Michael A Lemp; David A Sullivan Journal: Invest Ophthalmol Vis Sci Date: 2011-03-30 Impact factor: 4.799
Authors: Ashley Behrens; John J Doyle; Lee Stern; Roy S Chuck; Peter J McDonnell; Dimitri T Azar; Harminder S Dua; Milton Hom; Paul M Karpecki; Peter R Laibson; Michael A Lemp; David M Meisler; Juan Murube Del Castillo; Terrence P O'Brien; Stephen C Pflugfelder; Maurizio Rolando; Oliver D Schein; Berthold Seitz; Scheffer C Tseng; Gysbert van Setten; Steven E Wilson; Samuel C Yiu Journal: Cornea Date: 2006-09 Impact factor: 2.651
Authors: Henry D Perry; Renée Solomon; Eric D Donnenfeld; Alicia R Perry; John R Wittpenn; Herb E Greenman; Howard E Savage Journal: Arch Ophthalmol Date: 2008-08
Authors: Miguel Angel Pérez-Silguero; David Pérez-Silguero; Amado Rivero-Santana; Maria Inmaculada Bernal-Blasco; Pablo Encinas-Pisa Journal: Clin Ophthalmol Date: 2021-05-21